Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May;27(5):770-8.
doi: 10.1093/annonc/mdw015. Epub 2016 Jan 22.

New drugs in acute myeloid leukemia

T M Kadia  1 , F Ravandi  2 , J Cortes  2 , H Kantarjian  2
Affiliations
Review

New drugs in acute myeloid leukemia

T M Kadia et al. Ann Oncol. 2016 May.

Abstract

The standard therapy for acute myeloid leukemia (AML) has not changed meaningfully for the past four decades. Improvements in supportive care and modifications to the dose and schedule of existing agents have led to steady improvements in outcomes. However, developing new therapies for AML has been challenging. Although there have been advances in understanding the biology of AML, translating this knowledge to viable treatments has been slow. Active research is currently ongoing to address this important need and several promising drug candidates are currently in the pipeline. Here, we review some of the most advanced and promising compounds that are currently in clinical trials and may have the potential to be part of our future armamentarium. These drug candidates range from cytotoxic chemotherapies, targeted small-molecule inhibitors, and monoclonal antibodies.

Keywords: BCL2 inhibitor; FLT3 inhibitors; acute myeloid leukemia; monoclonal antibodies; new therapies; targeted therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kadia T, Kantarjian H, Garcia-Manero G et al. . Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol 2015; 170(4): 590–593. - PMC - PubMed
    1. Bross PF, Beitz J, Chen G et al. . Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7(6): 1490–1496. - PubMed
    1. Ravandi F, Estey EH, Appelbaum FR et al. . Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol 2012; 30(32): 3921–3923. - PMC - PubMed
    1. Dohner H, Estey EH, Amadori S et al. . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115(3): 453–474. - PubMed
    1. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015; 373(12): 1136–1152. - PubMed

Publication types

MeSH terms

Substances